ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2028

The Asia Pacific irritable bowel syndrome treatment market is set to project a CAGR of 8.92% during the forecast period, 2021-2028. The factors driving the market growth are the enhanced healthcare infrastructure, the increasing number of hospitals with advanced medical facilities, technological advancements, and the growing healthcare reforms.

asia-pacific-irritable-bowel-syndrome-treatment-market

To learn more about this report, request a free sample copy

The Asia Pacific irritable bowel syndrome treatment market growth assessment includes the analysis of Indonesia, Australia & New Zealand, China, Japan, South Korea, Vietnam, India, Thailand, and Rest of Asia Pacific. IBS (Irritable Bowel Syndrome) is prevalent among the Chinese population with constipation issues and painful & inconsistent bowel movements. The increasing awareness of IBS treatments has led to its increased market share. The geriatric population of China is expected to grow in the coming years. People aged 65 and above are more vulnerable to the hernia, given the weakening of muscles around the abdomen. According to the WHO data, the aged population is estimated to reach 28% by 2040. Several clinical trials have revealed that Chinese herbal, integrative, or acupuncture therapies have enhanced the treatment outcomes, reducing side-effects in IBS patients. Such factors are assessed to boost the market growth in China. In Thailand, the fastest-growing sector is healthcare. It is also projected to be the key driver of Thailand's economy, with the increasing healthcare expenditure. The aging population is also evaluated to increase to 20 million. Further, several huge conglomerate companies are increasingly investing in healthcare. Such factors are set to promote market growth in Thailand.

Takeda Pharmaceutical Company Limited (Takeda or 'the company') is engaged in the manufacture, marketing, research, and development of pharmaceutical products. The company has a strong product portfolio across core therapeutic areas like gastrointestinal, vaccines, oncology, CNS (central nervous system), etc. It has its headquarters in Tokyo, Japan.

TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. SCOPE OF STUDY
    3. METHODOLOGY
    4. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. RISE IN THE INCIDENCE OF GASTROINTESTINAL AILMENTS
      2. GROWING NUMBER OF DRUG DEVELOPMENTS AND FDA APPROVALS
      3. SURGING OCCURENCE OF IRRITABLE BOWEL SYNDROME
      4. INCREASING GERIATRIC POPULATION
    2. KEY RESTRAINTS
      1. HIGH COST OF DRUGS
      2. LACK OF SKILLED PROFESSIONALS IN DEVELOPING ECONOMIES
      3. LIMITED TREATMENT OPTIONS
  4. KEY ANALYTICS
    1. PORTER’S FIVE FORCES ANALYSIS
      1. THREAT OF NEW ENTRY
      2. THREAT OF SUBSTITUTION
      3. BUYER’S POWER
      4. SUPPLIER’S POWER
      5. COMPETITIVE RIVALRY
    2. IMPACT OF COVID-19 ON IRRITABLE BOWEL SYNDROME TREATMENT MARKET
    3. OPPORTUNITY MATRIX
    4. VENDOR LANDSCAPE
    5. KEY INVESTMENT INSIGHTS
  5. MARKET BY TYPE
    1. IBS WITH DIARRHEA
    2. IBS WITH CONSTIPATION
    3. MIXED IBS
  6. MARKET BY PRODUCT
    1. RIFAXIMIN
    2. ELUXADOLINE
    3. LINACLOTIDE
    4. LUBIPROSTONE
    5. OTHER PRODUCTS
  7. MARKET BY DISTRIBUTION CHANNEL
    1. DRUG STORES AND RETAIL PHARMACIES
    2. HOSPITALS’ PHARMACIES
    3. ONLINE PHARMACIES
  8. MARKET BY MECHANISM OF ACTION
    1. 5HT3 ANTAGONIST
    2. GUANYLATE CYCLASE RECEPTOR-C AGONIST
    3. CHLORIDE CHANNEL ACTIVATOR
    4. OTHER MECHANISM OF ACTIONS
  9. MARKET BY DOSAGE
    1. SOLID
    2. LIQUID
  10. GEOGRAPHICAL ANALYSIS
    1. ASIA PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. KEY GROWTH ENABLERS
      3. KEY CHALLENGES
      4. KEY PLAYERS
      5. COUNTRY ANALYSIS
        1. JAPAN
        2. CHINA
        3. AUSTRALIA & NEW ZEALAND
        4. INDIA
        5. SOUTH KOREA
        6. THAILAND
        7. INDONESIA
        8. VIETNAM
        9. REST OF ASIA PACIFIC
  11. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGER & ACQUISITIONS
      2. PRODUCT LAUNCH & DEVELOPMENTS
      3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
      4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
    2. COMPANY PROFILE
      1. ABBOTT LABORATORIES
      2. BAUSCH HEALTH COMPANIES INC
      3. ALLERGAN PLC
      4. ARDELYX INC
      5. ASTELLAS PHARMA INC
      6. ASTRAZENECA PLC
      7. GLAXOSMITHKLINE PLC
      8. IRONWOOD PHARMACEUTICALS INC
      9. JOHNSON & JOHNSON (MCNEIL CONSUMER HEALTHCARE)
      10. LANNETT COMPANY INC
      11. NOVARTIS AG
      12. SEBELA PHARMACEUTICALS INC
      13. SYNTHETIC BIOLOGICS INC
      14. TAKEDA PHARMACEUTICAL COMPANY LTD
LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - IRRITABLE BOWEL SYNDROME TREATMENT

TABLE 2: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 3: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 4: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 5: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 6: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 7: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 8: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 9: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 10: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 11: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 12: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 13: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 14: LEADING PLAYERS OPERATING IN ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET

LIST OF FIGURES

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, IN 2020

FIGURE 6: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH DIARRHEA, 2021-2028 (IN $ MILLION)

FIGURE 7: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH CONSTIPATION, 2021-2028 (IN $ MILLION)

FIGURE 8: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MIXED IBS, 2021-2028 (IN $ MILLION)

FIGURE 9: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, IN 2020

FIGURE 10: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY RIFAXIMIN, 2021-2028 (IN $ MILLION)

FIGURE 11: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ELUXADOLINE, 2021-2028 (IN $ MILLION)

FIGURE 12: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LINACLOTIDE, 2021-2028 (IN $ MILLION)

FIGURE 13: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LUBIPROSTONE, 2021-2028 (IN $ MILLION)

FIGURE 14: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER PRODUCTS, 2021-2028 (IN $ MILLION)

FIGURE 15: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, IN 2020

FIGURE 16: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DRUG STORES AND RETAIL PHARMACIES, 2021-2028 (IN $ MILLION)

FIGURE 17: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY HOSPITALS’ PHARMACIES, 2021-2028 (IN $ MILLION)

FIGURE 18: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ONLINE PHARMACIES, 2021-2028 (IN $ MILLION)

FIGURE 19: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, IN 2020

FIGURE 20: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY 5HT3 ANTAGONIST, 2021-2028 (IN $ MILLION)

FIGURE 21: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY GUANYLATE CYCLASE RECEPTOR-C AGONIST, 2021-2028 (IN $ MILLION)

FIGURE 22: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY CHLORIDE CHANNEL ACTIVATOR, 2021-2028 (IN $ MILLION)

FIGURE 23: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER MECHANISM OF ACTIONS, 2021-2028 (IN $ MILLION)

FIGURE 24: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, IN 2020

FIGURE 25: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY SOLID, 2021-2028 (IN $ MILLION)

FIGURE 26: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LIQUID, 2021-2028 (IN $ MILLION)

FIGURE 27: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 28: JAPAN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 29: CHINA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 30: AUSTRALIA & NEW ZEALAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 31: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 32: SOUTH KOREA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 33: THAILAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 34: INDONESIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 35: VIETNAM IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 36: REST OF ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

Request For A Free Sample